In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis
Alvirez-Freites, E.J.; Carter, J.L.; Cynamon, M.H.
Antimicrobial Agents and ChemoTherapy 46(4): 1022-1025
2002
ISSN/ISBN: 0066-4804 PMID: 11897584 DOI: 10.1128/aac.46.4.1022-1025.2002
Accession: 003807448
Gatifloxacin (GAT) and moxifloxacin (MXF) were evaluated in vitro to determine their activities against M. tuberculosis. GAT was subsequently compared in a dose range study to isoniazid (INH) in a murine tuberculosis model. GAT was somewhat less active than INH. GAT and MXF were evaluated in mice infected with M. tuberculosis and were found to have similar activities.
Full Text Article emailed within 0-6 h: $19.90
Related References
Tomioka, H.; Sato, K.; Akaki, T.; Kajitani, H.; Kawahara, S.; Sakatani, M. 1999: Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin , gatifloxacin , and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex Antimicrobial Agents and Chemotherapy 43(12): 3001-3004Tomioka, H.; Sato, K.; Akaki, T.; Kajitani, H.; Kawahara, S.; Sakatani, M. 1999: Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex Antimicrobial Agents and ChemoTherapy 43(12): 3001-3004
Tomioka, H.; Sato, K.; Akaki, T.; Kajitani, H.; Kawahara, S.; Sakatani, M. 1999: Comparative In Vitro Antimicrobial Activities of the Newly Synthesized Quinolone Hsr-903, Sitafloxacin (Du-6859a), Gatifloxacin (Am-1155), and Levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium Complex Antimicrobial Agents and Chemotherapy 43(12): 3001-3004
Sano, C.; Tatano, Y.; Shimizu, T.; Yamabe, S.; Sato, K.; Tomioka, H. 2011: Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium International Journal of Antimicrobial Agents 37(4): 296-301
Gomez, C.; Ponien, P.; Serradji, N.; Lamouri, A.; Pantel, A.; Capton, E.; Jarlier, V.; Anquetin, G.; Aubry, A. 2013: Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis Bioorganic and Medicinal Chemistry 21(4): 948-956
Sriram, D.; Aubry, A.; Yogeeswari, P.; Fisher, L.M. 2006: Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase Bioorganic and Medicinal Chemistry Letters 16(11): 2982-2985
Upton, A.M.; Cho, S.; Yang, T.J.; Kim, Y.; Wang, Y.; Lu, Y.; Wang, B.; Xu, J.; Mdluli, K.; Ma, Z.; Franzblau, S.G. 2015: In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 59(1): 136-144
Lu, Y.; Zheng, M.-Q.; Wang, B.; Zhao, W.-J.; Li, P.; Chu, N.-H.; Liang, B.-W. 2008: Activities of clofazimine against Mycobacterium tuberculosis in vitro and in vivo Zhonghua Jie he He Hu Xi Za Zhi 31(10): 752-755
Ji, B.; Lounis, N.; Truffot-Pernot, C.; Grosset, J. 1995: In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 39(6): 1341-1344
Xu, J.; Wang, B.; Fu, L.; Zhu, H.; Guo, S.; Huang, H.; Yin, D.; Zhang, Y.; Lu, Y. 2019: In Vitro and in Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 63(5)
Shoen, C.; DeStefano, M.; Hafkin, B.; Cynamon, M. 2018: In Vitro and in Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 62(8)
Gay, J.D.; Deyoung, D.R.; Roberts, G.D. 1984: In vitro activities of norfloxacin and ciprofloxacin against mycobacterium tuberculosis mycobacterium avium complex mycobacterium chelonei mycobacterium fortuitum and mycobacterium kansasii Antimicrobial Agents and Chemotherapy 26(1): 94-96
Ashtekar, D.R.; Costa-Perira, R.; Nagrajan, K.; Vishvanathan, N.; Bhatt, A.D.; Rittel, W. 1993: In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis Antimicrobial Agents and Chemotherapy 37(2): 183-186
Hirata, T.; Saito, H.; Tomioka, H.; Sato, K.; Jidoi, J.; Hosoe, K.; Hidaka, T. 1995: In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 39(10): 2295-2303
Saito, H.; Tomioka, H.; Sato, K.; Hirata, T.; Hidaka, T. 1994: In vitro and in vivo activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis Abstracts of the General Meeting of the American Society for Microbiology 94: 192
Ji, B.; Lounis, N.; Maslo, C.; Truffot-Pernot, C.; Bonnafous, P.; Grosset, J. 1998: In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 42(8): 2066-2069
Falzari, K.; Zhu, Z.; Pan, D.; Liu, H.; Hongmanee, P.; Franzblau, S.G. 2005: In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 49(4): 1447-1454
Jagannath, C.; Allaudeen, H.S.; Hunter, R.L. 1995: Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo Antimicrobial Agents and ChemoTherapy 39(6): 1349-1354
Zhang, M.; Sala, C.; Dhar, N.; Vocat, A.; Sambandamurthy, V.K.; Sharma, S.; Marriner, G.; Balasubramanian, V.; Cole, S.T. 2014: In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 58(6): 3217-3223
Ji, B.; Truffot-Pernot, C.; Grosset, J. 1991: In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis Tubercle 72(3): 181-186